Tempus AI, Inc. $TEM Shares Sold by Royal Bank of Canada

Royal Bank of Canada reduced its stake in Tempus AI, Inc. (NASDAQ:TEM) by 62.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 26,828 shares of the company’s stock after selling 45,555 shares during the quarter. Royal Bank of Canada’s holdings in Tempus AI were worth $1,212,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA lifted its stake in Tempus AI by 291.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after acquiring an additional 36,096 shares in the last quarter. Bogart Wealth LLC grew its position in Tempus AI by 365,087.5% in the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after acquiring an additional 58,414 shares in the last quarter. Eagle Health Investments LP purchased a new stake in Tempus AI during the first quarter worth about $11,588,000. Alethea Capital Management LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth about $1,863,000. Finally, Hussman Strategic Advisors Inc. lifted its position in shares of Tempus AI by 100.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock worth $2,480,000 after purchasing an additional 21,000 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of TEM opened at $66.65 on Friday. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32. The stock has a market capitalization of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The stock has a 50-day simple moving average of $52.44 and a 200-day simple moving average of $51.21.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. On average, analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Ryan M. Bartolucci sold 6,175 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $306,341.75. Following the sale, the chief accounting officer directly owned 67,866 shares in the company, valued at approximately $3,366,832.26. This trade represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 26,313 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the transaction, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. The trade was a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 943,202 shares of company stock worth $46,417,587. Corporate insiders own 24.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TEM. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. BTIG Research increased their target price on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Hold” and an average target price of $65.69.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.